JP2016507470A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507470A5
JP2016507470A5 JP2015540879A JP2015540879A JP2016507470A5 JP 2016507470 A5 JP2016507470 A5 JP 2016507470A5 JP 2015540879 A JP2015540879 A JP 2015540879A JP 2015540879 A JP2015540879 A JP 2015540879A JP 2016507470 A5 JP2016507470 A5 JP 2016507470A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antigen
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540879A
Other languages
English (en)
Japanese (ja)
Other versions
JP6694269B2 (ja
JP2016507470A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/068624 external-priority patent/WO2014074540A2/en
Publication of JP2016507470A publication Critical patent/JP2016507470A/ja
Publication of JP2016507470A5 publication Critical patent/JP2016507470A5/ja
Application granted granted Critical
Publication of JP6694269B2 publication Critical patent/JP6694269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540879A 2012-11-06 2013-11-06 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 Active JP6694269B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US61/723,137 2012-11-06
US201361782405P 2013-03-14 2013-03-14
US61/782,405 2013-03-14
PCT/US2013/068624 WO2014074540A2 (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019011283A Division JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Publications (3)

Publication Number Publication Date
JP2016507470A JP2016507470A (ja) 2016-03-10
JP2016507470A5 true JP2016507470A5 (enExample) 2016-12-22
JP6694269B2 JP6694269B2 (ja) 2020-05-13

Family

ID=50685304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540879A Active JP6694269B2 (ja) 2012-11-06 2013-11-06 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
JP2019011283A Withdrawn JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019011283A Withdrawn JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Country Status (16)

Country Link
US (3) US9879070B2 (enExample)
EP (2) EP3640338A1 (enExample)
JP (2) JP6694269B2 (enExample)
KR (1) KR102288394B1 (enExample)
CN (2) CN104968797B (enExample)
AU (2) AU2013341361A1 (enExample)
BR (1) BR112015010125A2 (enExample)
CA (1) CA2890427C (enExample)
DK (1) DK2917360T3 (enExample)
ES (1) ES2776179T3 (enExample)
HU (1) HUE049012T2 (enExample)
MX (2) MX375324B (enExample)
PL (1) PL2917360T3 (enExample)
RU (1) RU2698131C2 (enExample)
SG (2) SG10201703678TA (enExample)
WO (1) WO2014074540A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913690SA (en) * 2011-02-08 2020-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944B1 (en) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
KR20150092738A (ko) 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
PH12018501429B1 (en) * 2014-06-03 2022-04-27 Xbiotech Inc Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016023943A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (fr) * 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
CN107873034A (zh) * 2015-04-17 2018-04-03 阿尔萨尼斯生物科学有限责任公司 抗金黄色葡萄球菌抗体组合制剂
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
CN105424930A (zh) * 2015-11-23 2016-03-23 天津科技大学 一种快速检测金黄色葡萄球菌的方法
SG11202001160XA (en) * 2017-09-29 2020-03-30 Regeneron Pharma Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
TWI902669B (zh) * 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
WO2020076789A2 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
EP3864040A1 (en) 2018-10-09 2021-08-18 Medimmune, LLC Antibodies directed against staphylococcus aureus leukotoxins
US12459991B2 (en) 2019-02-12 2025-11-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
TW202100549A (zh) 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법
KR102674120B1 (ko) * 2021-01-18 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 면역분석 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002072600A2 (en) * 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
EP1638514A4 (en) * 2003-06-06 2009-11-18 Medimmune Inc USE OF EPHA4 AND MODULATOR OR EPHA4 FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER
JP2007528720A (ja) 2003-08-12 2007-10-18 ダイアックス コーポレイション Ｔｉｅ１結合リガンド
AU2005271523B2 (en) * 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
CA2638833A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2719397A1 (en) * 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
WO2008152447A2 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
PL2244722T3 (pl) * 2008-01-31 2017-04-28 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Leczenie zakażeń drobnoustrojami
AU2009246510B2 (en) * 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
WO2010005513A2 (en) * 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
WO2010042481A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
EP2432499A2 (en) * 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
BRPI1015567A2 (pt) * 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
BR112012000953A8 (pt) * 2009-07-15 2017-12-26 Aimm Therapeutics Bv anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
EP2555794A4 (en) * 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
SG10201913690SA (en) * 2011-02-08 2020-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
EP2744517B1 (en) * 2011-08-15 2019-03-13 The University of Chicago Compositions and methods related to antibodies to staphylococcal protein a
HRP20201004T1 (hr) * 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
HRP20201127T1 (hr) * 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
KR20150092738A (ko) * 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EP3057988A2 (en) * 2013-10-15 2016-08-24 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
US20170023569A1 (en) * 2014-01-10 2017-01-26 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
JP6556758B2 (ja) * 2014-01-24 2019-08-07 チャーチ、ウィリアム、アール． 黄色ブドウ球菌特異的抗体、それを用いた治療方法及び検出方法
PH12018501429B1 (en) * 2014-06-03 2022-04-27 Xbiotech Inc Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
CN107873034A (zh) 2015-04-17 2018-04-03 阿尔萨尼斯生物科学有限责任公司 抗金黄色葡萄球菌抗体组合制剂
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
CA3030154A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
TWI902669B (zh) * 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
EP3864040A1 (en) * 2018-10-09 2021-08-18 Medimmune, LLC Antibodies directed against staphylococcus aureus leukotoxins
WO2020076789A2 (en) * 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
TW202100549A (zh) * 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染

Similar Documents

Publication Publication Date Title
JP2016507470A5 (enExample)
RU2015121624A (ru) Антитела к поверхностным детерминантам s. aureus
JP2012010714A5 (enExample)
JP2021063090A5 (enExample)
JP2015514110A5 (enExample)
JP2019536806A5 (enExample)
JP2014205674A5 (enExample)
JP2014511179A5 (enExample)
JP2020500538A5 (enExample)
JP2015503909A5 (enExample)
JP2018535650A5 (enExample)
JP2017507652A5 (enExample)
JP2014519334A5 (enExample)
JP2017514461A5 (enExample)
JP2012504634A5 (enExample)
JP2017052784A5 (enExample)
JP2017528476A5 (enExample)
JP2016536361A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2010516229A5 (enExample)
JP2011514150A5 (enExample)
JP2006522830A5 (enExample)
JP2014526898A5 (enExample)
JP2010526028A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4